Last reviewed · How we verify
Probiotic : Saccharomyces boulardii
Saccharomyces boulardii is a live yeast probiotic that restores healthy gut microbiota and strengthens intestinal barrier function to prevent pathogenic colonization and reduce gastrointestinal inflammation.
Saccharomyces boulardii is a live yeast probiotic that restores healthy gut microbiota and strengthens intestinal barrier function to prevent pathogenic colonization and reduce gastrointestinal inflammation. Used for Acute diarrhea (viral and bacterial), Antibiotic-associated diarrhea, Traveler's diarrhea.
At a glance
| Generic name | Probiotic : Saccharomyces boulardii |
|---|---|
| Sponsor | Biocodex |
| Drug class | Probiotic |
| Modality | Biologic |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
This non-pathogenic yeast strain produces antimicrobial compounds and competitive exclusion factors that inhibit harmful bacteria and toxins from adhering to the intestinal epithelium. It also enhances tight junction integrity and modulates local immune responses through interaction with gut-associated lymphoid tissue, reducing intestinal permeability and inflammation.
Approved indications
- Acute diarrhea (viral and bacterial)
- Antibiotic-associated diarrhea
- Traveler's diarrhea
- Clostridium difficile-associated diarrhea
- Irritable bowel syndrome
Common side effects
- Fungemia (rare, primarily in immunocompromised patients)
- Mild gastrointestinal symptoms (bloating, gas)
Key clinical trials
- Probiotics, Antibiotics and the Post-Antibiotic Microbiota (NA)
- Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation (NA)
- Effect of Probiotics on Relapsing-Remitting Multiple Sclerosis (NA)
- Effects of Saccharomyces Boulardii CNCM I-745 on Antibiotic-Associated Perturbation in Children Treated for Acute Respiratory Infections (RESTORE Study) (PHASE4)
- Combined Rehabilitation and Nutritional Support vs. Standard Care in In-Hospital Endocarditis Treatment (NA)
- A Trial of a Multi-Component Nutritional Supplement in Hydrogen-Dominant Small Intestinal Bacterial Overgrowth (NA)
- Probiotics to Actively Counter Ventilator Associated Pneumonia (PROACT) (NA)
- Zinc Plus Saccharomyces Boulardii Versus Zinc Alone in the Treatment of Acute Diarrhea (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotic : Saccharomyces boulardii CI brief — competitive landscape report
- Probiotic : Saccharomyces boulardii updates RSS · CI watch RSS
- Biocodex portfolio CI